SANTA MONICA, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it will report its financial results for the year ended December 31, 2018, after the market close, and will host a corporate update conference call and webcast on Thursday, March 21, at 4:30 p.m. Eastern Time.
|Conference Call Details |
|Thursday, March 21st @ 4:30pm Eastern Time/1:30pm Pacific Time |
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing medicines for addictions and drug overdose. National Institute on Drug Abuse, a division of the National Institutes of Health, describes addictive disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Opiant's first drug overdose product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by its commercialization partner, Adapt Pharmaceuticals, now owned by Emergent BioSolutions, Inc. For more information visit: www.opiant.com.
For Media Inquiries:
Julie Normart, W2O Group
For Investor Inquiries:
Dan Ferry, LifeSci Advisors, LLC